Akira Kuzuya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Akira Kuzuya has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Ryosuke Takahashi
Office of Research Acceleration, Kyoto University
3 shared publicationsKengo Uemura
Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2 shared publications- Masato Maesako
Alzheimer Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School
2 shared publications Naoyuki Kitagawa
Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2 shared publicationsAkio Ikeda
Department of Epilepsy, Movement Disorders, and Physiology, Kyoto University Graduate School of Medicine
1 shared publication- Akio Ikeda
Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication
Latest Publications
- Open Access
- 12 October 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1807027
Case Report: Longitudinal evaluation of cerebrospinal fluid Alzheimer’s disease core biomarkers in a case of refractory late-onset epilepsy of unknown etiology
In recent years, late-onset epilepsy of unknown etiology (LOEU) has increasingly been recognized as a risk factor for Alzheimer’s disease (AD) and other forms of dementia. We present a case of refractory LOEU with progressive cognitive decline, longitudinally evaluated over more than 20 years using neuropsychological tests, cerebrospinal fluid (CSF) AD core biomarkers (Aβ42/40 ratio, p-tau), electroencephalography, and neuroimaging. The CSF AD core biomarkers were consistently positive, indicating the presence of both amyloid and tau pathology; however, CSF Aβ levels markedly decreased in parallel with improved seizure control. Notably, the addition of low-dose perampanel (1 mg/day) led to improvement in both cognitive function and seizure control, while 18 F-flutemetamol positron emission tomography remained visually negative despite exceeding the predefined quantitative Centiloid threshold. Two years later, seizure frequency increased again, cognitive function deteriorated, and amyloid PET became visually positive, accompanied by an increase in the quantitative Centiloid value. This longitudinal observation suggests that chronic epileptic activity may modify or confound the interpretation of CSF AD biomarker profiles and contribute to cognitive decline, while concomitant early or slowly progressive AD pathology cannot be excluded. The overall biomarker trajectory, including persistently positive CSF AD biomarkers and progressive amyloid PET findings, is compatible with evolving AD pathology, although the marked decline in absolute CSF Aβ concentrations during improved seizure control suggests that chronic epileptic activity may also influence biomarker dynamics. Careful interpretation of AD biomarkers is therefore essential in patients with LOEU, particularly in the era of anti-amyloid therapies.
- 12 October 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1807027
Open AccessCase Report: Longitudinal evaluation of cerebrospinal fluid Alzheimer’s disease core biomarkers in a case of refractory late-onset epilepsy of unknown etiology
In recent years, late-onset epilepsy of unknown etiology (LOEU) has increasingly been recognized as a risk factor for Alzheimer’s disease (AD) and other forms of dementia. We present a case of refractory LOEU with progressive cognitive decline, longitudinally evaluated over more than 20 years using neuropsychological tests, cerebrospinal fluid (CSF) AD core biomarkers (Aβ42/40 ratio, p-tau), electroencephalography, and neuroimaging. The CSF AD core biomarkers were consistently positive, indicating the presence of both amyloid and tau pathology; however, CSF Aβ levels markedly decreased in parallel with improved seizure control. Notably, the addition of low-dose perampanel (1 mg/day) led to improvement in both cognitive function and seizure control, while 18 F-flutemetamol positron emission tomography remained visually negative despite exceeding the predefined quantitative Centiloid threshold. Two years later, seizure frequency increased again, cognitive function deteriorated, and amyloid PET became visually positive, accompanied by an increase in the quantitative Centiloid value. This longitudinal observation suggests that chronic epileptic activity may modify or confound the interpretation of CSF AD biomarker profiles and contribute to cognitive decline, while concomitant early or slowly progressive AD pathology cannot be excluded. The overall biomarker trajectory, including persistently positive CSF AD biomarkers and progressive amyloid PET findings, is compatible with evolving AD pathology, although the marked decline in absolute CSF Aβ concentrations during improved seizure control suggests that chronic epileptic activity may also influence biomarker dynamics. Careful interpretation of AD biomarkers is therefore essential in patients with LOEU, particularly in the era of anti-amyloid therapies.
- Open Access
- 1 January 2024
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (1)
Resident Memory-like CD8 + T Cells Are Involved in Chronic Inflammatory and Neurodegenerative Diseases in the CNS
Background and Objectives Resident memory T (Trm) cells are a unique population that can survive and function in a compartmentalized tissue with inflammatory potential. We aim to investigate the alteration of Trm population in acute/chronic inflammatory and neurodegenerative diseases in the CNS. Methods The frequencies of CD4+ and CD8+ T cells expressing both CD69 and CD103, the markers for Trm cells, were quantified in the peripheral blood and CSF (n = 80 and 44, respectively) in a cross-sectional manner. The transcriptional profile of Trm-like population in the CSF was further analyzed using a public single-cell dataset. Results The frequency of CD69+CD103+CD8+ T cells was strikingly higher in the CSF than in the peripheral blood (among memory fraction, 13.5% vs 0.11%, difference (mean [SE]): 13.4% [2.9]). This CD69+CD103+CD8+ T-cell population was increased in the CSF from patients with chronic inflammatory diseases including multiple sclerosis and with neurodegenerative diseases such as Parkinson disease and Alzheimer disease compared with controls (11.5%, 13.0%, 8.1% vs 2.9%, respectively). By contrast, the frequency was not altered in acute inflammatory conditions in the CNS (4.0%). Single-cell RNAseq analysis confirmed Trm signature in CD69+CD103+CD8+ T cells in the CSF, supporting their Trm-like phenotype, which was not clear in controls. Discussion Collectively, an increase in CD69+CD103+CD8+ Trm-like population in the CSF is related with both chronic neuroinflammatory and some neurodegenerative diseases in the CNS, suggesting a partially shared pathology in these diseases.
- 1 January 2024
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (1)
Open AccessResident Memory-like CD8 + T Cells Are Involved in Chronic Inflammatory and Neurodegenerative Diseases in the CNS
Background and Objectives Resident memory T (Trm) cells are a unique population that can survive and function in a compartmentalized tissue with inflammatory potential. We aim to investigate the alteration of Trm population in acute/chronic inflammatory and neurodegenerative diseases in the CNS. Methods The frequencies of CD4+ and CD8+ T cells expressing both CD69 and CD103, the markers for Trm cells, were quantified in the peripheral blood and CSF (n = 80 and 44, respectively) in a cross-sectional manner. The transcriptional profile of Trm-like population in the CSF was further analyzed using a public single-cell dataset. Results The frequency of CD69+CD103+CD8+ T cells was strikingly higher in the CSF than in the peripheral blood (among memory fraction, 13.5% vs 0.11%, difference (mean [SE]): 13.4% [2.9]). This CD69+CD103+CD8+ T-cell population was increased in the CSF from patients with chronic inflammatory diseases including multiple sclerosis and with neurodegenerative diseases such as Parkinson disease and Alzheimer disease compared with controls (11.5%, 13.0%, 8.1% vs 2.9%, respectively). By contrast, the frequency was not altered in acute inflammatory conditions in the CNS (4.0%). Single-cell RNAseq analysis confirmed Trm signature in CD69+CD103+CD8+ T cells in the CSF, supporting their Trm-like phenotype, which was not clear in controls. Discussion Collectively, an increase in CD69+CD103+CD8+ Trm-like population in the CSF is related with both chronic neuroinflammatory and some neurodegenerative diseases in the CNS, suggesting a partially shared pathology in these diseases.
- Open Access
- 18 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23252
Acute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models
Hippocampal hyperexcitability is a promising therapeutic target to prevent Aβ deposition in AD since enhanced neuronal activity promotes presynaptic Aβ production and release. This article highlights the potential application of perampanel (PER), an AMPA receptor (AMPAR) antagonist approved for partial seizures, as a therapeutic agent for AD. Using transgenic AD mice combined with in vivo brain microdialysis and primary neurons under oligomeric Aβ‐evoked neuronal hyperexcitability, the acute effects of PER on Aβ metabolism were investigated. A single oral administration of PER rapidly decreased ISF Aβ 40 and Aβ 42 levels in the hippocampus of J20, APP transgenic mice, without affecting the Aβ 40 /Aβ 42 ratio; 5 mg/kg PER resulted in declines of 20% and 31%, respectively. Moreover, PER‐treated J20 manifested a marked decrease in hippocampal APP βCTF levels with increased FL‐APP levels. Consistently, acute treatment of PER reduced sAPPβ levels, a direct byproduct of β‐cleavage of APP, released to the medium in primary neuronal cultures under oligomeric Aβ‐induced neuronal hyperexcitability. To further evaluate the effect of PER on ISF Aβ clearance, a γ‐secretase inhibitor was administered to J20 1 h after PER treatment. PER did not influence the elimination of ISF Aβ, indicating that the acute effect of PER is predominantly on Aβ production. In conclusion, acute treatment of PER reduces Aβ production by suppressing β‐cleavage of amyloid‐β precursor protein effectively, indicating a potential effect of PER against Aβ pathology in AD.
- 18 October 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23252
Open AccessAcute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models
Hippocampal hyperexcitability is a promising therapeutic target to prevent Aβ deposition in AD since enhanced neuronal activity promotes presynaptic Aβ production and release. This article highlights the potential application of perampanel (PER), an AMPA receptor (AMPAR) antagonist approved for partial seizures, as a therapeutic agent for AD. Using transgenic AD mice combined with in vivo brain microdialysis and primary neurons under oligomeric Aβ‐evoked neuronal hyperexcitability, the acute effects of PER on Aβ metabolism were investigated. A single oral administration of PER rapidly decreased ISF Aβ 40 and Aβ 42 levels in the hippocampus of J20, APP transgenic mice, without affecting the Aβ 40 /Aβ 42 ratio; 5 mg/kg PER resulted in declines of 20% and 31%, respectively. Moreover, PER‐treated J20 manifested a marked decrease in hippocampal APP βCTF levels with increased FL‐APP levels. Consistently, acute treatment of PER reduced sAPPβ levels, a direct byproduct of β‐cleavage of APP, released to the medium in primary neuronal cultures under oligomeric Aβ‐induced neuronal hyperexcitability. To further evaluate the effect of PER on ISF Aβ clearance, a γ‐secretase inhibitor was administered to J20 1 h after PER treatment. PER did not influence the elimination of ISF Aβ, indicating that the acute effect of PER is predominantly on Aβ production. In conclusion, acute treatment of PER reduces Aβ production by suppressing β‐cleavage of amyloid‐β precursor protein effectively, indicating a potential effect of PER against Aβ pathology in AD.
- Open Access
- 24 October 2018
- Published by Springer Nature in Molecular Brain
- Vol. 11 (1) , 61
Fibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid β production in Alzheimer’s disease
The deposition of Amyloid-beta peptides (Aβ) is detected at an earlier stage in Alzheimer’s disease (AD) pathology. Thus, the approach toward Aβ metabolism is considered to play a critical role in the onset and progression of AD. Mounting evidence suggests that lifestyle-related diseases are closely associated with AD, and exercise is especially linked to the prevention and the delayed progression of AD. We previously showed that exercise is more effective than diet control against Aβ pathology and cognitive deficit in AD mice fed a high-fat diet; however, the underlying molecular mechanisms remain poorly understood. On the other hand, a report suggested that exercise induced expression of fibronectin type III domain-containing protein 5 (FNDC5) in the hippocampus of mice through PGC1α pathway. Thus, in the current study, we investigated a possibility that FNDC5 interacts with amyloid precursor protein (APP) and affects Aβ metabolism. As a result, for the first time ever, we found the interaction between FNDC5 and APP, and forced expression of FNDC5 significantly decreased levels of both Aβ40 and Aβ42 secreted in the media. Taken together, our results indicate that FNDC5 significantly affects β-cleavage of APP via the interaction with APP, finally regulating Aβ levels. A deeper understanding of the mechanisms by which the interaction between APP and FNDC5 may affect Aβ production in an exercise-dependent manner would provide new preventive strategies against the development of AD.
- 24 October 2018
- Published by Springer Nature in Molecular Brain
- Vol. 11 (1) , 61
Open AccessFibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid β production in Alzheimer’s disease
The deposition of Amyloid-beta peptides (Aβ) is detected at an earlier stage in Alzheimer’s disease (AD) pathology. Thus, the approach toward Aβ metabolism is considered to play a critical role in the onset and progression of AD. Mounting evidence suggests that lifestyle-related diseases are closely associated with AD, and exercise is especially linked to the prevention and the delayed progression of AD. We previously showed that exercise is more effective than diet control against Aβ pathology and cognitive deficit in AD mice fed a high-fat diet; however, the underlying molecular mechanisms remain poorly understood. On the other hand, a report suggested that exercise induced expression of fibronectin type III domain-containing protein 5 (FNDC5) in the hippocampus of mice through PGC1α pathway. Thus, in the current study, we investigated a possibility that FNDC5 interacts with amyloid precursor protein (APP) and affects Aβ metabolism. As a result, for the first time ever, we found the interaction between FNDC5 and APP, and forced expression of FNDC5 significantly decreased levels of both Aβ40 and Aβ42 secreted in the media. Taken together, our results indicate that FNDC5 significantly affects β-cleavage of APP via the interaction with APP, finally regulating Aβ levels. A deeper understanding of the mechanisms by which the interaction between APP and FNDC5 may affect Aβ production in an exercise-dependent manner would provide new preventive strategies against the development of AD.
- Open Access
- 31 March 2016
- Published by Springer Nature in BMC Biology
- Vol. 14 (1) , 1-24
Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta
Synaptic loss strongly correlates with memory deterioration. Local accumulation of amyloid β (Aβ) peptide, and neurotoxic Aβ42 in particular, due to abnormal neuronal activity may underlie synaptic dysfunction, neurodegeneration, and memory impairments. To gain an insight into molecular events underlying neuronal activity-regulated Aβ production at the synapse, we explored functional outcomes of the newly discovered calcium-dependent interaction between Alzheimer’s disease-associated presenilin 1 (PS1)/γ-secretase and synaptic vesicle proteins. Mass spectrometry screen of mouse brain lysates identified synaptotagmin 1 (Syt1) as a novel synapse-specific PS1-binding partner that shows Ca2+-dependent PS1 binding profiles in vitro and in vivo. We found that Aβ level, and more critically, conformation of the PS1 and the Aβ42/40 ratio, are affected by Syt1 overexpression or knockdown, indicating that Syt1 and its interaction with PS1 might regulate Aβ production at the synapse. Moreover, β-secretase 1 (BACE1) stability, β- and γ-secretase activity, as well as intracellular compartmentalization of PS1 and BACE1, but not of amyloid precursor protein (APP), nicastrin (Nct), presenilin enhancer 2 (Pen-2), or synaptophysin (Syp) were altered in the absence of Syt1, suggesting a selective effect of Syt1 on PS1 and BACE1 trafficking. Our findings identify Syt1 as a novel Ca2+-sensitive PS1 modulator that could regulate synaptic Aβ, opening avenues for novel and selective synapse targeting therapeutic strategies.
- 31 March 2016
- Published by Springer Nature in BMC Biology
- Vol. 14 (1) , 1-24
Open AccessIdentification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta
Synaptic loss strongly correlates with memory deterioration. Local accumulation of amyloid β (Aβ) peptide, and neurotoxic Aβ42 in particular, due to abnormal neuronal activity may underlie synaptic dysfunction, neurodegeneration, and memory impairments. To gain an insight into molecular events underlying neuronal activity-regulated Aβ production at the synapse, we explored functional outcomes of the newly discovered calcium-dependent interaction between Alzheimer’s disease-associated presenilin 1 (PS1)/γ-secretase and synaptic vesicle proteins. Mass spectrometry screen of mouse brain lysates identified synaptotagmin 1 (Syt1) as a novel synapse-specific PS1-binding partner that shows Ca2+-dependent PS1 binding profiles in vitro and in vivo. We found that Aβ level, and more critically, conformation of the PS1 and the Aβ42/40 ratio, are affected by Syt1 overexpression or knockdown, indicating that Syt1 and its interaction with PS1 might regulate Aβ production at the synapse. Moreover, β-secretase 1 (BACE1) stability, β- and γ-secretase activity, as well as intracellular compartmentalization of PS1 and BACE1, but not of amyloid precursor protein (APP), nicastrin (Nct), presenilin enhancer 2 (Pen-2), or synaptophysin (Syp) were altered in the absence of Syt1, suggesting a selective effect of Syt1 on PS1 and BACE1 trafficking. Our findings identify Syt1 as a novel Ca2+-sensitive PS1 modulator that could regulate synaptic Aβ, opening avenues for novel and selective synapse targeting therapeutic strategies.
- 30 October 2006
- Published by Wiley in Journal of Neuroscience Research
- Vol. 85 (1) , 153-165
Presenilin 1 is involved in the maturation of β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1)
One of the pathologic hallmarks of Alzheimer's disease is the excessive deposition of β-amyloid peptides (Aβ) in senile plaques. Aβ is generated when β-amyloid precursor protein (APP) is cleaved sequentially by β-secretase, identified as β-site APP-cleaving enzyme 1 (BACE1), and γ-secretase, a putative enzymatic complex containing presenilin 1 (PS1). However, functional interaction between PS1 and BACE1 has never been known. In addition to this classical role in the generation of Aβ peptides, it has also been proposed that PS1 affects the intracellular trafficking and maturation of selected membrane proteins. We show that the levels of exogenous and endogenous mature BACE1 expressed in presenilin-deficient mouse embryonic fibroblasts (PS−/−MEFs) were reduced significantly compared to those in wild-type MEFs. Moreover, the levels of mature BACE1 were increased in human neuroblastoma cell line, SH-SY5Y, stably expressing wild-type PS1, compared to native cells. Conversely, the maturation of BACE1 was compromised under the stable expression of dominant–negative mutant PS1 overexpression. Immunoprecipitation assay showed that PS1 preferably interacts with proBACE1 rather than mature BACE1, indicating that PS1 can be directly involved in the maturation process of BACE1. Further, endogenous PS1 was immunoprecipitated with endogenous BACE1 in SH-SY5Y cells and mouse brain tissue. We conclude that PS1 is directly involved in the maturation of BACE1, thus possibly functioning as a regulator of both β- and γ-secretase in Aβ generation.
- 30 October 2006
- Published by Wiley in Journal of Neuroscience Research
- Vol. 85 (1) , 153-165
Presenilin 1 is involved in the maturation of β‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1)
One of the pathologic hallmarks of Alzheimer's disease is the excessive deposition of β-amyloid peptides (Aβ) in senile plaques. Aβ is generated when β-amyloid precursor protein (APP) is cleaved sequentially by β-secretase, identified as β-site APP-cleaving enzyme 1 (BACE1), and γ-secretase, a putative enzymatic complex containing presenilin 1 (PS1). However, functional interaction between PS1 and BACE1 has never been known. In addition to this classical role in the generation of Aβ peptides, it has also been proposed that PS1 affects the intracellular trafficking and maturation of selected membrane proteins. We show that the levels of exogenous and endogenous mature BACE1 expressed in presenilin-deficient mouse embryonic fibroblasts (PS−/−MEFs) were reduced significantly compared to those in wild-type MEFs. Moreover, the levels of mature BACE1 were increased in human neuroblastoma cell line, SH-SY5Y, stably expressing wild-type PS1, compared to native cells. Conversely, the maturation of BACE1 was compromised under the stable expression of dominant–negative mutant PS1 overexpression. Immunoprecipitation assay showed that PS1 preferably interacts with proBACE1 rather than mature BACE1, indicating that PS1 can be directly involved in the maturation process of BACE1. Further, endogenous PS1 was immunoprecipitated with endogenous BACE1 in SH-SY5Y cells and mouse brain tissue. We conclude that PS1 is directly involved in the maturation of BACE1, thus possibly functioning as a regulator of both β- and γ-secretase in Aβ generation.
- 23 May 2003
- Published by Wiley in Journal of Neuroscience Research
- Vol. 73 (2) , 166-175
Presenilin 1 mediates retinoic acid‐induced differentiation of SH‐SY5Y cells through facilitation of Wnt signaling
Presenilin 1 interacts with β‐catenin, an essential component of the Wnt signaling pathway. To elucidate the role of presenilin 1‐β‐catenin interaction in neuronal differentiation, we established SH‐SY5Y cells stably expressing wild‐type presenilin 1, P117L mutant presenilin 1, which is linked to the early‐onset familial form of Alzheimer's disease, and D385A mutant presenilin 1, which has no aspartyl proteinase activity. We demonstrate that SH‐SY5Y cells stably expressing D385A mutant presenilin 1 failed to differentiate in response to retinoic acid treatment. Retinoic acid caused an increase in nuclear β‐catenin levels in SH‐SY5Y cells, which was followed by an increase in cyclin D1 protein levels. Abnormal cellular accumulation of β‐catenin was observed in D385A mutant transfected cells, whereas nuclear β‐catenin and cellular cyclin D1 levels failed to increase. Conversely, SH‐SY5Y cells expressing the P117L mutant differentiated normally and showed increased nuclear β‐catenin and cellular cyclin D1 levels. These findings suggest that neuronal differentiation of SH‐SY5Y cells involves the Wnt signaling pathway and that presenilin 1 plays a crucial role in Wnt signal transduction by regulating the nuclear translocation of β‐catenin.
- 23 May 2003
- Published by Wiley in Journal of Neuroscience Research
- Vol. 73 (2) , 166-175
Presenilin 1 mediates retinoic acid‐induced differentiation of SH‐SY5Y cells through facilitation of Wnt signaling
Presenilin 1 interacts with β‐catenin, an essential component of the Wnt signaling pathway. To elucidate the role of presenilin 1‐β‐catenin interaction in neuronal differentiation, we established SH‐SY5Y cells stably expressing wild‐type presenilin 1, P117L mutant presenilin 1, which is linked to the early‐onset familial form of Alzheimer's disease, and D385A mutant presenilin 1, which has no aspartyl proteinase activity. We demonstrate that SH‐SY5Y cells stably expressing D385A mutant presenilin 1 failed to differentiate in response to retinoic acid treatment. Retinoic acid caused an increase in nuclear β‐catenin levels in SH‐SY5Y cells, which was followed by an increase in cyclin D1 protein levels. Abnormal cellular accumulation of β‐catenin was observed in D385A mutant transfected cells, whereas nuclear β‐catenin and cellular cyclin D1 levels failed to increase. Conversely, SH‐SY5Y cells expressing the P117L mutant differentiated normally and showed increased nuclear β‐catenin and cellular cyclin D1 levels. These findings suggest that neuronal differentiation of SH‐SY5Y cells involves the Wnt signaling pathway and that presenilin 1 plays a crucial role in Wnt signal transduction by regulating the nuclear translocation of β‐catenin.